A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan

NCT06635057 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication tirzepatide in adults with type 2 diabetes to see how it affects blood sugar levels during the month of Ramadan.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 166 people

Who can join Ages 18+ · all sexes

Timeline Started 2024-10 · est. completion 2026-04

Where 29 sites · Saudi Arabia, United Arab Emirates

What this study is testing ClinicalTrials.gov NCT06635057 ↗

Description as written by the study sponsor.

The main purpose of the study is to investigate whether tirzepatide can be effectively started before Ramadan and used per label in participants with Type 2 Diabetes during the fasting month.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC

Main thing measured	Change from Baseline in Hemoglobin A1c (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06635057 ↗